摘要
探究血必净注射液联合非诺贝特对高脂血症性急性重症胰腺炎的临床疗效及安全性。选取贵州航天医院2022年2月—2025年2月收治的76例高脂血症性急性重症胰腺炎患者为研究对象,随机将其分为A组、B组,每组各38例。A组采取非诺贝特治疗,B组采取血必净注射液联合非诺贝特治疗,比较两组患者的治疗效果、治疗前后实验室检查指标及不良反应发生情况。结果显示,B组治疗有效率高于A组(P<0.05);治疗7天时,B组胰腺炎CT评分以及三酰甘油(TG)、C-反应蛋白(CRP)、淀粉酶、肌酸激酶(CK)、乳酸脱氢酶(LDH)、血肌酐(Scr)、尿素氮(BUN)水平均低于A组(P<0.05);治疗期间两组患者均未见明显不良反应。研究发现,对高脂血症性急性重症胰腺炎患者应用血必净注射液联合非诺贝特治疗,可提升患者的治疗效果,降低患者机体的炎症反应程度,改善患者的心脏、肾脏功能指标,且安全性良好。
This study explores the clinical efficacy and safety of Xuebijing Injection combined with fenofi brate in the treatment of hyperlipidemic severe acute pancreatitis(HSAP).A total of 76 HSAP patients admitted to Guizhou Aerospace Hospital from February 2022 to February 2025 were randomly divided into Group A(38 cases)and Group B(38 cases).Group A was treated with fenofi brate alone,while Group B received Xuebijing Injection combined with fenofi brate.The therapeutic effects,laboratory indices before and after treatment,and adverse reactions were compared between the two groups.The results showed that the effective rate of Group B was significantly higher than that of Group A(P<0.05).On day 7 of treatment,the CT score for pancreatitis and the levels of triglyceride(TG),C-reactive protein(CRP),amylase,creatine kinase(CK),lactate dehydrogenase(LDH),serum creatinine(Scr),and blood urea nitrogen(BUN)in Group B were all lower than those in Group A(P<0.05).No obvious adverse reactions were observed in both groups during treatment.The study indicates that the combination of Xuebijing Injection and fenofi brate can improve the therapeutic effect,reduce the degree of infl ammatory response,and improve cardiac and renal function indices in HSAP patients,with good safety.
作者
柯棠山
张灿灿
莫朝华
王海生
佘小双
吴祥琴
Ke Tangshan;Zhang Cancan;Mo Zhaohua;Wang Haisheng;She Xiaoshuang;Wu Xiangqin(Guizhou Aerospace Hospital,Zunyi,Guizhou 563000)
出处
《科技与健康》
2025年第11期77-80,共4页
Technology and Health
基金
合肥市科技计划项目(遵市科合HZ字[2024]115号)。
关键词
高脂血症性急性重症胰腺炎
血必净
非诺贝特
hyperlipidemic severe acute pancreatitis
Xuebijing Injection
fenofi brate
